Krystal Biotech, Inc. KRYS Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Krystal Biotech, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The official record: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Krystal Biotech, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Krystal Biotech, Inc.'s cash & equivalents?
- Krystal Biotech, Inc. (KRYS) reported cash & equivalents of $501.31M in Q1 2026.
- How has Krystal Biotech, Inc.'s cash & equivalents changed year-over-year?
- Krystal Biotech, Inc.'s cash & equivalents increased by 62.4% year-over-year, from $308.77M to $501.31M.
- What is the long-term trend for Krystal Biotech, Inc.'s cash & equivalents?
- Over 5 years (2020 to 2025), Krystal Biotech, Inc.'s cash & equivalents has grown at a 13.1% compound annual growth rate (CAGR), from $268.27M to $496.3M.
- What does cash & equivalents mean?
- The total amount of cash and highly liquid assets the company has on hand.
- How do you interpret cash & equivalents?
- An increase suggests improved liquidity and financial flexibility, while a decrease may indicate high cash burn or significant capital deployment.
- How does cash & equivalents compare across companies?
- Standard across all industries; peers in biotech typically hold higher levels to support multi-year clinical trials.